Cross-sectional Association Between Prolactin Levels and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: a Retrospective Analysis of Patients from a Single Hospital in China

Overview

Journal BMJ Open

Specialty General Medicine

Date 2022 Oct 3

PMID 36192106

Authors

Yuanyuan Zhang

Huaizhen Liu

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to retrospectively assess the association between prolactin (PRL) and non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).

Design And Setting: A retrospective, cross-sectional study was conducted at a single hospital in Anhui, China.

Participants: A total of 406 patients with T2DM (230 men and 176 women) was included.

Outcome Measures: P values for the independent t-test, the Mann-Whitney rank-sum test, the Spearman correlation analysis and multiple logistic regression models were used to explore the association between PRL and NAFLD in patients with T2DM.

Results: The results indicated that in both men and women, the levels of PRL were significantly lower in the T2DM with NAFLD group than in the T2DM without NAFLD group (men: 9.56 ng/mL vs 10.36 ng/mL, women: 10.38 ng/mL vs 12.97 ng/mL). In male patients, the levels of PRL were negatively correlated with hip circumference (r=-0.141, p=0.032), homoeostasis model assessment for insulin resistance (C-peptide) (r=-0.141, p=0.032) and triglyceride (TG) (r=-0.252, p=0.000) values and inversely correlated with high-density lipoprotein (r=0.147, p=0.025) levels. In female patients, PRL levels were negatively related to body mass index (r=-0.192, p=0.011), diastolic blood pressure (r=-0.220, p=0.003), waist circumference (r=-0.152, p=0.044), hip circumference (r=-0.157, p=0.037) and TG (r=-0.258, p=0.001) values. Logistic regression analysis revealed a negative relationship between PRL and NAFLD (men: OR 0.891, 95% CI 0.803 to 0.989, p=0.031; women: OR 0.874, 95% CI 0.797 to 0.957, p=0.004). As PRL levels increased, NAFLD prevalence decreased in both sexes (men: p=0.012, women: p=0.013).

Conclusion: Our results suggest that low levels of PRL in the physiological range were markers of NAFLD in patients with T2DM and that PRL within the biologically high range may play a protective role in the pathogenesis of NAFLD.

Citing Articles

The beneficial and detrimental effects of prolactin hormone on metabolic syndrome: A double-edge sword.

Zaidalkilani A, Al-Kuraishy H, Al-Gareeb A, Alexiou A, Papadakis M, Al-Farga A J Cell Mol Med. 2024; 28(23):e70067.

PMID: 39663784 PMC: 11635126. DOI: 10.1111/jcmm.70067.

The homeo-FIT-prolactin hypothesis: the role of prolactin in metabolic homeostasis - association or causality?.

Krogh J Rev Endocr Metab Disord. 2024; 25(6):1077-1086.

PMID: 39388004 DOI: 10.1007/s11154-024-09916-7.

Serum prolactin levels were positively related to metabolic indexes and disorders in male obese patients.

Ke X, Wang L, Zhao Y, Duan L, Deng K, Yao Y Endocrine. 2024; 84(3):1097-1107.

PMID: 38396200 DOI: 10.1007/s12020-024-03743-1.

Ectopic lipid metabolism in anterior pituitary dysfunction.

Baumgartner C, Krssak M, Vila G, Krebs M, Wolf P Front Endocrinol (Lausanne). 2023; 14:1075776.

PMID: 36860364 PMC: 9968795. DOI: 10.3389/fendo.2023.1075776.

References

Huang H, Lee S, Sousa-Lima I, Kim S, Hwang W, Dagon Y . Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. J Clin Invest. 2018; 128(12):5335-5350. PMC: 6264719. DOI: 10.1172/JCI63562. View

Wang F, Fan J, Zhang Z, Gao B, Wang H . The global burden of liver disease: the major impact of China. Hepatology. 2014; 60(6):2099-108. PMC: 4867229. DOI: 10.1002/hep.27406. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Mantovani A, Turino T, Lando M, Gjini K, Byrne C, Zusi C . Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 2019; 46(4):296-303. DOI: 10.1016/j.diabet.2019.11.004. View

Fan J, Farrell G . Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2008; 50(1):204-10. DOI: 10.1016/j.jhep.2008.10.010. View

Manshaei N, Shakibaei F, Fazilati M, Salavati H, Negahdary M, Palizban A . An investigation of the association between the level of prolactin in serum and type II diabetes. Diabetes Metab Syndr. 2018; 13(5):3035-3041. DOI: 10.1016/j.dsx.2018.07.007. View

Hogan J, Stephens J . The regulation of fatty acid synthase by STAT5A. Diabetes. 2005; 54(7):1968-75. DOI: 10.2337/diabetes.54.7.1968. View

Friedrich N, Schneider H, Spielhagen C, Markus M, Haring R, Grabe H . The association of serum prolactin concentration with inflammatory biomarkers - cross-sectional findings from the population-based Study of Health in Pomerania. Clin Endocrinol (Oxf). 2011; 75(4):561-6. DOI: 10.1111/j.1365-2265.2011.04075.x. View

Pappachan J, Babu S, Krishnan B, Ravindran N . Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Transl Hepatol. 2017; 5(4):384-393. PMC: 5719196. DOI: 10.14218/JCTH.2017.00013. View

10.

Wang T, Lu J, Xu Y, Li M, Sun J, Zhang J . Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care. 2013; 36(7):1974-80. PMC: 3687322. DOI: 10.2337/dc12-1893. View

11.

Nilsson L, Roepstorff C, Kiens B, Billig H, Ling C . Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Horm Metab Res. 2009; 41(10):747-51. DOI: 10.1055/s-0029-1224181. View

12.

Yip S, Romano N, Gustafson P, Hodson D, Williams E, Kokay I . Elevated Prolactin during Pregnancy Drives a Phenotypic Switch in Mouse Hypothalamic Dopaminergic Neurons. Cell Rep. 2019; 26(7):1787-1799.e5. DOI: 10.1016/j.celrep.2019.01.067. View

13.

Goffin V, Binart N, Touraine P, Kelly P . Prolactin: the new biology of an old hormone. Annu Rev Physiol. 2002; 64:47-67. DOI: 10.1146/annurev.physiol.64.081501.131049. View

14.

Rinella M . Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015; 313(22):2263-73. DOI: 10.1001/jama.2015.5370. View

15.

Zhang L, Curhan G, Forman J . Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens. 2010; 28(7):1400-5. PMC: 3139424. DOI: 10.1097/HJH.0b013e328339f254. View

16.

Yang H, Di J, Pan J, Yu R, Teng Y, Cai Z . The Association Between Prolactin and Metabolic Parameters in PCOS Women: A Retrospective Analysis. Front Endocrinol (Lausanne). 2020; 11:263. PMC: 7235367. DOI: 10.3389/fendo.2020.00263. View

17.

de Castro L, Dos Santos A, Casulari L, Naves L, Amato A . Association between variations of physiological prolactin serum levels and the risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2020; 166:108247. DOI: 10.1016/j.diabres.2020.108247. View

18.

Rhee E . Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Endocrinol Metab (Seoul). 2019; 34(3):226-233. PMC: 6769345. DOI: 10.3803/EnM.2019.34.3.226. View

19.

Anstee Q, Targher G, Day C . Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10(6):330-44. DOI: 10.1038/nrgastro.2013.41. View

20.

Abram C, Lowell C . The ins and outs of leukocyte integrin signaling. Annu Rev Immunol. 2009; 27:339-62. PMC: 3248397. DOI: 10.1146/annurev.immunol.021908.132554. View